ALOX12B and adenocarcinoma: In 230 patients with adenocarcinoma from the TCGA cohort, higher expressions of MYH9, GNB1, and ALOX12B were associated with poor overall survival outcomes, while higher expression of HSD17B4 was associated with better survival outcomes (Figure S4B) [23].